If you can’t see where #AVCT is headed after digesting the latest written Q&A, you never will.
In summary:
- yes, we’re already talking to the FDA about accelerated approval. Our P2 will be 80-100 patients. Big. And we’re still not worried about cash… why do you think that is?
- data is such we’re re-evaluating whether to go for more common indications in P2 (no doubt informed by the bi-weekly data). An expedited approach may also be possible here, depending on FDA discussions.
- we have 28.5 months of detailed data, we did not present it because we will seek further IP protections and present this rich data set at the major conferences in early 2024
And just in case you still don’t get we’re not worried about cash (because we will strike a deal):
“More broadly, our commercial strategy includes partnering of the pre|CISION platform to enable third parties to develop pre|CISION chemotherapies under license using their own proprietary cytotoxics. We believe that approach provides the best opportunity to maximise the benefits to our stakeholders”
And if you *still* don’t get it, they go again:
“Avacta therefore plans to take AVA6000 into phase 2 and will then consider partnering this asset to take it to market and to broaden its applications into other cancer indications.
There is potential to partner AVA3996 or any other undisclosed pipeline assets at a preclinical stage. More importantly in the short term is the potential to partner the pre|CISION platform.
This means potentially licensing the platform to a third party to use in combination with their own cytotoxic agent.
Such a licensing deal would be expected to be narrowly focused on a specific agent or agents. The clinical data published on December 13th 2023 plays a pivotal role in generating business development discussions and accelerating those that are ongoing.”
You’re going to wake up one morning very soon to Avacta having signed a license deal for preCISION.
I can’t quite believe the SP sits <200p, let alone below where it was before the trial began (124p) on this Q&A but there you go. It does.
The unadulterated madness of AIM.
Tears of joy today.
A momentous day in the War on Cancer and a beacon of light for sufferers of the horrible disease.
Huge congratulations to team @avacta#AVCT for delivering this astonishing scientific breakthrough.
This marks the beginning of the revolution in chemotherapy.
@Cumulus51896691@tom_the_bomb__@BobDibble8 Interesting. A few months ago (pre latest DE) I had a little anxiety.
Now I have zero. The only anxiety is waiting for everyone else to catch up and a sensible chance of success to be ascribed.
My relaxation is best exemplified by EnergyShares on the #AVCT lse bb.
👇
@YorkshirPuddin@Stocksniper28@Towlie1981 Sounds to me like this guy knows fuck all😂 Shorting a company without knowing what he’s actually shorting. Crazy how someone can be so negative about AV6000 when it has the potential to be life changing for millions. My thinking is that his short isn’t going too well.. 55p👀
On #WorldCancerDay we are proud to be a part of the global effort to improve patient’s lives through more advanced cancer treatments. Find out about the exciting work taking place at Avacta with our pre|CISION™ and Affimer® platforms: https://t.co/IATdd6WVM6
Our best 200 stock picks for 2022!
Yes an incredible response - & MASSIVE THANKS.
Currently the Top 10 in descending order are:
#acp , #AVCT , #DDDD , #KIST , #BOO , #TGR, #EML , #sng , #SAVE#AGL
@KirkShares@Borg74 Well if your following people into trades without knowing the consequences… it proves that you are actually the idiot for following 🤣